High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study

References

• Pecoraro V, De Santis E, Melegari A, Trenti T. The impact of immunogenicity of TNFα inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis. Autoimmun Rev. 2017;16(6):564–75. doi:10.1016/j.autrev.2017.04.002.
   PubMed Web of Science ®Google Scholar
• Croxtall JD. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs. 2011;71(13):1731–53. doi:10.2165/11207530-000000000-00000.
   Web of Science ®Google Scholar
• Saco TV, Strauss AT, Ledford DK. Hepatitis B vaccine non-responders: possible mechanisms and solutions. AnnAllergy Asthma Immunol. 2018;121(3):320–27. doi:10.1016/j.anai.2018.03.017.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global hepatitis report 2017. Geneva; 2017 [accessed 2018 June]. www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
   Google Scholar
• Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind doseresponse study. BMJ. 1997;314(7077):329–33. doi:10.1136/bmj.314.7077.329.
   PubMedGoogle Scholar
• Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, Rodewald LE, Douglas JM, Janssen RS, Ward JW. Centers for disease control and prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis b virus infection in the United States recommendations of the advisory committee on immunization practices (ACIP) Part II: immunization of adults. MMWR RecommRep. 2006;55:1–33.
   PubMedGoogle Scholar
• Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–19. doi:10.1053/j.gastro.2014.10.039.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98. doi:10.1016/j.jhep.2017.03.021.
   PubMed Web of Science ®Google Scholar
• Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection – an update. Microb Cell. 2016;3(9):420–37. doi:10.15698/mic2016.09.527.
   PubMed Web of Science ®Google Scholar
• Uner A, Kirimi E, Tuncer I, Ceylan A, Turkdogan MK, Abuhandan M. Seroepidemiology of hepatitis B virus infection in children in the Eastern Anatolia. East J Med. 2001;6:40–42.
   Google Scholar
• Demirpence O, Sahin H, Gumus A, Korkmaz E, Hakim F, Uysal F. HbsAg and anti HCV seroprevalence in an eastern province of Turkey. Cumhuriyet Med J. 2016;38(1):29–34. doi:10.7197/cmj.v38i1.5000156049.
   Google Scholar
• Tosun S. Hepatitis B virus vaccine. Viral Hepat Jl. 2012;18(2):37–46. doi:10.4274/Vhd.24633.
   Google Scholar
• Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo T, Salpietro C, Rosa ML, Leonardi S. Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol. 2014;20(30):10383–94. doi:10.3748/wjg.v20.i30.10383.
   PubMed Web of Science ®Google Scholar
• Salinas GF, Rycke LD, Barendregt B, Paramarta JE, Hreggvidstdottir H, Cantaert T, Bur M, Tak PP, Baeten D. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis. 2013;72(6):1037–43. doi:10.1136/annrheumdis-2011-201270.
   PubMed Web of Science ®Google Scholar
• Aringer M. Vaccination under TNF blockade - less effective, but worthwhile. Arthritis Res Ther. 2012;14(3):117. doi:10.1186/ar3808.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Cantini F, Goletti D, Gomez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumour necrosis factor-α agents). Clin Microbiol Infect. 2018;24(2):10–20. doi:10.1016/j.cmi.2017.12.025.
   PubMedGoogle Scholar
• Ravikumar R, Owen T, Barnard J, Divekar AA, Conley T, Cushing E, Mosmann TR, Sanz I, Looney J, Anolik J, et al. Anti-TNF therapy in RA patiens alters hepatitis B vaccine responses. Arthritis Rheum. 2006;56:36.
   Google Scholar
• Moses J, Alkhouri N, Shannon A, Raig K, Lopez R, Danziger-Isakov L, Feldstein AE, Zein NN, Wyllie R, Carter-Kent C. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol. 2012;107:133–38. doi:10.1038/ajg.2011.295.
   PubMed Web of Science ®Google Scholar
• Tosun SY, Karaca M, Ertilav M, Akkum K. The evaluation of hepatitis B vaccine efficacy used in health care centers. TurkiyeKlinikleri J Pediatr. 2003;12:77–80.
   Google Scholar
• McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, Khristova M, Zanis C, Peters H, Margolis HS. Antibody levels and protection after hepatitis B vaccination: results of a 15-Year Follow-up. Ann Intern Med. 2005;142(5):333–41. doi:10.7326/0003-4819-142-5-200503010-00008.
   PubMed Web of Science ®Google Scholar
• Duman H, Meuer S, Meyer zumBuschenfelde KH, Köhler H. Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure. Kidney Int. 1990;38:1164–68.
   PubMed Web of Science ®Google Scholar
• Mena G, García-Basteiro AL, Bayas JM. Hepatitis B and A vaccination in HIV-infected adults: A review. Hum Vaccin Immunother. 2015;11(1):2582–98. doi:10.1080/21645515.2015.1055424.
   PubMedGoogle Scholar
• Feng Y, Shi J, Gao L, Yao T, Feng D, Luo D, Li Z, Zhang Y, Wang F, Cui F, et al. Immunogenicity and safety of high-dose hepatitis B vaccine among drug users: A randomized, open-labeled, blank-controlled trial. Hum VaccinImmunother. 2017;13(6):1297–303. doi:10.1080/21645515.2017.1283082.
   PubMed Web of Science ®Google Scholar
• Aggeletopoulou I, Davoulou P, Konstantakis C, Thomopoulos K, Triantos C. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol. 2017;27(6):1942. doi:10.1002/rmv.1942.
   Web of Science ®Google Scholar
• Clemens R, Sanger R, Kruppenbacher J, Höbel W, Stanbury W, Bock HL, Jilg W. Booster immunization of low- and non-responders after a Standard three dose hepatitis B vaccine scheduleresults of a post-marketing surveillance. Vaccine. 1997;15:349–52.
   PubMed Web of Science ®Google Scholar
• Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med. 1998;15:1–8.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Moutschen M, Gompel AV, Ranst MV, Louis E, Segaert S, Masson P, De Keyser F. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatolog. 2010;49(10):1815–27. doi:10.1093/rheumatology/keq183.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(10):1460–66. doi:10.1038/ajg.2012.79.
   PubMed Web of Science ®Google Scholar